Kaplan-Meier analysis of survival and cumulative incidence of relapse following allogeneic HSCT in MDS patients stratified according to their pre-transplant IPSS cytogenetic risk or the new MDS cytogenetic scoring system used for the IPSS-R. (A) There was a significant difference in posttransplant OS between patients with poor IPSS cytogenetics and those with good (P = .002) or intermediate IPSS cytogenetics (P = .03), whereas no significant difference was found between good and intermediate IPSS cytogenetics (P = .31). (B) Patients with poor IPSS cytogenetics also showed a significantly higher probability of relapse than those with good (P < .001) and intermediate IPSS cytogenetics (P = .02). (C) There was a significant difference in posttransplant OS between patients with good and those with poor (P = .03) or very poor IPSS-R cytogenetics (P = .002), whereas no significant difference was seen between good and intermediate IPSS-R cytogenetics (P = .10). Patients with intermediate IPSS-R cytogenetics had an increased OS compared with those with poor or very poor IPSS-R cytogenetics (P = .02). (D) The cumulative incidence of relapse was lower in patients with good IPSS-R cytogenetics than in those with intermediate, poor, or very poor IPSS-R cytogenetics (P = .006, P = .001, and P < .001, respectively). Patients with intermediate IPSS-R cytogenetics showed a significantly lower incidence of relapse than those with poor or very poor IPSS-R cytogenetics (P = .04).